linsitinib
linsitinib is a pharmaceutical drug with 8 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
2
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Clinical Trials (8)
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8